The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
The market size for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) has seen significant growth recently. The market is set to increase from $10.36 billion in 2024 to $13.32 billion in 2025, with a compound annual growth rate (CAGR) of 28.5%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Industry?
The global market for transthyretin amyloid cardiomyopathy (ATTR-CM) treatment is predicted to reach $35.93 billion in 2029, with a compound annual growth rate (CAGR) of 28.2%.
Download Your Free Sample of the 2025 Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
The key drivers in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market are:
• Increased prevalence of transthyretin amyloidosis fuels demand for treatment.
• A rise in the diagnosis of neuropathic disorders contributes to market growth.
• An aging population demographic elevates the need for ATTR-CM treatment.
• Growing demand for specific drugs to treat symptoms of this rare disorder drives market expansion.
Global Market Segmentation: Identifying Major Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Industry Segments
The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market covered in this report is segmented –
1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types
2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Transthyretin Stabilizers: Tafamidis, Diflunisal
2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen, Other NSAIDs
3) By RNAi Therapy: Patisiran, Vutrisiran
4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies
Pre-order the 2025 Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Global Market Report for Fast Delivery & Comprehensive Insights!
What are the emerging Trends Shaping the Future of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
The key trends in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market are:
• New diagnostic technologies are trending in the market.
• The development of innovative techniques for therapy management is shaping the future of the market.
• There is a growing trend for innovative and targeted treatments for transthyretin amyloidosis.
• Advancements in diagnostic techniques, particularly cardiac MRI techniques, are a significant trend in the market.
Who Are the Top Competitors & Leading Players in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
Major players in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market are:
• Pfizer Inc.
• Bayer AG.
• AstraZeneca Plc
• GlaxoSmithKline Plc.
• Takeda Pharmaceutical Company Limited
• Novo Nordisk A/S
• Regeneron Pharmaceuticals Inc.
• MedStar Health Inc
• Alnylam Pharmaceuticals Inc
• Ionis Pharmaceuticals Inc.
• Akcea Therapeutics Inc
• BridgeBio Pharma Inc.
• Prothena Corporation plc
• Intellia Therapeutics Inc.
• Alexion Pharmaceuticals Inc.
• Neurimmune Holding AG
• SOM Biotech S.L
• Corino Therapeutics Inc
• Eidos Therapeutics Inc
• CRISPR Therapeutics AG
Regional Dominance: Which Area Leads the Global Template Market?
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024
